irinotecan + paclitaxel + docetaxel

The combination of irinotecan, paclitaxel, and docetaxel refers to a selection of cytotoxic chemotherapy agents used as the investigator's choice control arm in clinical trials, such as the Phase III study of the B7-H3-targeted antibody-drug conjugate (ADC) HS-20093. This grouping includes irinotecan, a topoisomerase I inhibitor that prevents DNA religation during replication, and the taxanes paclitaxel and docetaxel, which are microtubule-stabilizing agents that disrupt mitotic spindle function. In the context of second-line treatment for esophageal squamous cell carcinoma (ESCC), these agents are typically administered as monotherapies based on clinical discretion rather than as a concurrent triple combination. They serve as standard-of-care options for patients who have progressed after first-line platinum-based chemotherapy and immune checkpoint inhibitors.

Other names

Investigator's Choice Chemotherapy